Suppl Table 4. Demographics of the entire cohort of patients with adrenocortical carcinoma (n=942). Data collected at the time of diagnosis.

Variable	Value
Age, years	50 (38, 61)
Male, n(%)	359 (38)
Symptoms, n(%)	665 (71)
Symptom type, n(%)	
None	277 (29)
Tumour mass	175 (19)
Steroids	386 (41)
Cancer-related	40 (4)
Combinations of the above	64 (7)
Hormone pattern, n(%)	
Non-functional	360 (38)
Glucocorticoid excess	202 (21)
Androgen excess	80 (8)
Mineralocorticoid excess	25 (3)
Combinations of the above or other	196 (21)
Unknown	79 (8)
ENSAT tumour stage at diagnosis, n(%)	
1	86 (9)
2	474 (50)
3	218 (23)
4	164 (17)
mENSAT tumour stage at diagnosis, n(%)*	
4a	84 (9)
4b	35 (4)
4c	14 (1)
Unknown	31 (3)
Ki67 index	18 (8, 30)
Ki67 index (categories), n(%)	
0-9	264 (28)
10-19	216 (23)
≥20	462 (49)

Resection status of primary tumour, n(%)	
R0	648 (69)
RX	104 (11)
R1	56 (6)
R2	134 (14)
S-GRAS group, n(%)	
0-1	168 (18)
2-3	366 (39)
4-5	225 (24)
6-9	183 (19)
Disease recurrence, progress or death^, n(%)	572 (61)
Disease-specific death, n(%)	281 (30)
Death of any cause, n(%)	295 (31)
Median progression-free survival, months (95% CI)	21 (19, 24)
Median disease-specific survival, months (95% CI)	123 (89, not reached)
Median overall survival, months (95% CI)	104 (84, 164)

Continuous variables presented as median (and interquartile range).

*modified ENSAT staging for patients with metastatic disease at diagnosis (8) ^disease-related death

Median follow-up times: PFS: 49.63 months (95% CI 46.03, 58.77) and DSS: 45.00 months (95% CI 41.00, 48.00).